Pfizer lung cancer drug beats chemo for previously untreated patients

(Reuters) - Pfizer Inc's Xalkori delayed progression of lung cancer longer than chemotherapy in patients who had never previously been treated for the disease, according to results of a late-stage study released on Tuesday. The medicine, which received U.S. approval in 2011 for lung cancer patients who have a specific gene mutation, had shown in a previous Phase III trial that it significantly delayed disease progression among those who have already undergone chemotherapy for non-small-cell lung cancer, the most common form of the illness. The mutation only occurs in a small percentage of patients with lung cancer, but makes them good candidates for treatment with Xalkori. Pfizer is also developing an array of other cancer medicines that work through new mechanisms, with the aim of becoming a major player in the oncology field.



via Health News Headlines - Yahoo News http://ift.tt/1jBS7ZN